Ian Davis/LinkedIn
Jul 28, 2025, 03:49
Ian Davis: Two Opinions That Are Either Unpopular or Not Widely Held
Ian Davis, Professor of Medicine at Monash University and Eastern Health and Director and Chair of ANZUP, shared a post on X:
“Two opinions that to my surprise are either unpopular or not widely held:
- The control arm of a randomised trial should be best standard of care.
- A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.”
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on by Ian Davis, adding:
“Agree 100%. These shouldn’t be controversial. These are just common sense.”
More posts featuring Ian Davis and Bishal Gyawali on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 9, 2025, 17:43
Sep 9, 2025, 16:51
Sep 9, 2025, 15:59
Sep 9, 2025, 15:49
Sep 9, 2025, 15:46